2022
Open-Capsule Budesonide for the Treatment of Isolated Immune Checkpoint Inhibitor-Induced Enteritis
Hussain N, Robert M, Al-Bawardy B. Open-Capsule Budesonide for the Treatment of Isolated Immune Checkpoint Inhibitor-Induced Enteritis. ACG Case Reports Journal 2022, 9: e00882. PMID: 36237281, PMCID: PMC9553371, DOI: 10.14309/crj.0000000000000882.Peer-Reviewed Original Research
2020
Elective Colectomy in a Patient with Active Ulcerative Colitis and Metastatic Melanoma Enabling Successful Treatment with Immune Checkpoint Inhibitors.
Perdigoto AL, Tran T, Patel N, Clark P, Patell K, Stamatouli AM, Reddy V, Clune J, Herold KC, Robert ME, Kluger HM. Elective Colectomy in a Patient with Active Ulcerative Colitis and Metastatic Melanoma Enabling Successful Treatment with Immune Checkpoint Inhibitors. Clinical Oncology Case Reports 2020, 3 PMID: 33778814, PMCID: PMC7993656.Peer-Reviewed Original ResearchCheckpoint inhibitor therapyElective colectomyUlcerative colitisInhibitor therapyMetastatic melanomaImmune-related adverse eventsExcellent tumor responseImmune checkpoint inhibitorsSevere ulcerative colitisActive ulcerative colitisCheckpoint inhibitor immunotherapyCheckpoint inhibitor treatmentInflammatory bowel diseaseEffective treatment optionBenefits of treatmentImmune system activationTumor cell destructionCheckpoint inhibitorsAdvanced malignanciesAdverse eventsSelect patientsBowel diseaseAutoimmune diseasesTreatment optionsTumor responseImmune Checkpoint Inhibitor–Induced Upper Gastrointestinal Tract Inflammation Shows Morphologic Similarities to, but Is Immunologically Distinct From, Helicobacter pylori Gastritis and Celiac Disease
Irshaid L, Robert ME, Zhang X. Immune Checkpoint Inhibitor–Induced Upper Gastrointestinal Tract Inflammation Shows Morphologic Similarities to, but Is Immunologically Distinct From, Helicobacter pylori Gastritis and Celiac Disease. Archives Of Pathology & Laboratory Medicine 2020, 145: 191-200. PMID: 33501492, DOI: 10.5858/arpa.2019-0700-oa.Peer-Reviewed Original ResearchConceptsHelicobacter pylori gastritisUpper gastrointestinal tractCeliac diseasePylori gastritisCPI therapyCD8 ratioDuodenal biopsiesInflammatory changesLymphoid aggregatesGastrointestinal tractAnti-programmed death receptor-1/Anti-cytotoxic T-lymphocyteDeath receptor-1/Immune checkpoint inhibitor therapyImmune-related adverse eventsDeath ligand 1 antibodyColonic mucosal changesGastrointestinal tract inflammationLamina propria CD3Lamina propria inflammationUpper gastrointestinal biopsiesUpper gastrointestinal injuryCheckpoint inhibitor therapyH pylori gastritisCD8 T cells